Effectiveness and safety of varenicline for smoking cessation

被引：1

作者：

Christalla, P. ^{[1
]}

Dewenter, M. ^{[1
]}

El-Armouche, A. ^{[1
]}

机构：

[1] Univ Med Gottingen, Abt Pharmakol, D-37075 Gottingen, Germany

来源：

DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT | 2012年 / 137卷 / 18期

关键词：

nicotine dependence; smoking cessation; varenicline; nicotine receptor partial agonist; RECEPTOR PARTIAL AGONIST; SUSTAINED-RELEASE BUPROPION; CARDIOVASCULAR EVENTS; EFFICACY; PLACEBO; RISK;

D O I：

10.1055/s-0032-1304895

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Smoking is one of the major avoidable risks for mortality and morbidity. Thus developing new strategies for smoking cessation is a crucial medical challenge. Varenicline is an 2 nicotinic acetylcholine receptor partial agonist developed especially for smoking cessation. Several trials proved the efficacy of varenicline and its superiority to other medications for smoking cessation (bupropion and nicotine replacement therapy). Varenicline was associated with severe cardiovascular and neuro-psychiatric side effects. This article discusses the current research data on efficacy and safety of varenicline therapy for smoking cessation. © Georg Thieme Verlag KG · Stuttgart · New York.

引用

页码：940 / 944

页数：5

共 19 条

[1]

[Anonymous], 2008, NIC FACH

[2]

[Anonymous], 2011, ZYB FACH

[3]

[Anonymous], 2009, TAB DEUTSCHL 2009

[4] Varenicline:: An α4β2 nicotinic receptor partial agonist for smoking cessation [J].

Coe, JW ;

Brooks, PR ;

Vetelino, MG ;

Wirtz, MC ;

Arnold, EP ;

Huang, JH ;

Sands, SB ;

Davis, TI ;

Lebel, LA ;

Fox, CB ;

Shrikhande, A ;

Heym, JH ;

Schaeffer, E ;

Rollema, H ;

Lu, Y ;

Mansbach, RS ;

Chambers, LK ;

Rovetti, CC ;

Schulz, DW ;

Tingley, FD ;

O'Neill, BT .

JOURNAL OF MEDICINAL CHEMISTRY, 2005, 48 (10) :3474-3477

[5] Nicotinic acetylcholine receptors and nicotinic cholinergic mechanisms of the central nervous system [J].

Dani, John A. ;

Bertrand, Daniel .

ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, 2007, 47 :699-729

[6]

European Medicines Agency, 2011, EMA5793512011

[7]

FDA Drug Safety Newsletter, 2009, POSTMARKET REV

[8] Varenicline, an α4β2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation -: A randomized controlled trial [J].

Gonzales, David ;

Rennard, Stephen I. ;

Nides, Mitchell ;

Oncken, Cheryl ;

Azoulay, Salomon ;

Billing, Clare B. ;

Watsky, Eric J. ;

Gong, Jason ;

Williams, Kathryn E. ;

Reeves, Karen R. .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2006, 296 (01) :47-55

[9] Varenicline and suicidal behaviour: a cohort study based on data from the General Practice Research Database [J].

Gunnell, D. ;

Irvine, D. ;

Wise, L. ;

Davies, C. ;

Martin, R. M. .

BRITISH MEDICAL JOURNAL, 2009, 339 :1072

[10] Cardiovascular Events in Patients taking Varenicline A Case Series from Intensive Postmarketing Surveillance in New Zealand [J].

Harrison-Woolrych, Mira ;

Maggo, Simran ;

Tan, Ming ;

Savage, Ruth ;

Ashton, Janette .

DRUG SAFETY, 2012, 35 (01) :33-43

← 1 2 →